On December 31, the joint prevention and control mechanism of the State Council released that Sinopharm China Bio new crown inactivated vaccine has been approved by the State Food and Drug Administration for conditional listing.
According to the data released by Sinopharm group, the protection rate of the vaccine is 79.34%, achieving the unity of safety, effectiveness, accessibility and affordability, meeting the relevant standards of the World Health Organization and the State Food and drug administration. In the future, the persistence and protective effect of the vaccine should be observed continuously.
The National Health Commission said that China's vaccine research and development has always been in the first place in the world. Vaccination work for key groups has been started, vaccination will be carried out in an orderly manner, and qualified people will receive as much as possible.
In addition, Zeng Yixin, deputy director of the National Health Commission, said that a certain proportion of adverse reactions have also occurred in vaccination, and the overall incidence is very close to the inactivated vaccines given routinely. The main manifestations are local pain and local induration.
Zeng Yixin also said that the incidence of mild fever is less than 0.1%, and the incidence of allergic reactions and other serious adverse reactions is about 2 parts per million. These cases were treated in a timely manner and received good treatment.
According to the latest news of Sinopharm group, through statistical analysis, the results of the interim analysis of the phase III clinical trial of Sinopharm China biological Beijing company's new coronavirus inactivated vaccine show that the safety of the vaccine is good after vaccination. After two injections of the immunization procedure, the vaccinees in the vaccine group produce high titer antibodies, and the positive conversion rate of neutralizing antibodies is 99.52%.
The novel coronavirus vaccine (COVID-19) was protected against 79.34% of the disease caused by the new crown virus infection, and the data met the relevant technical standards of WHO and the relevant standard requirements of the guidelines for clinical evaluation of new coronavirus preventive vaccines issued by the State Administration of drug control.
China's new crown vaccine R & D has deployed five technical routes at the same time. At present, a total of 15 vaccines have entered different stages of clinical trials, and five have carried out phase III clinical trials. The number is among the top in the world, including two inactivated vaccines of Sinopharm sinobio.
- THE END -
Reprint please indicate the source: fast technology